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Radiogenomics is the whole genome application of radiogenetics, 
which studies the influence of genetic variation on radiation response. 
Work in the area focuses on uncovering the underlying common 
genetic causes of individual variation in sensitivity to radiation, which 
is important for effective, safe treatment. Many radiogenomics 
studies published to-date, have used a candidate gene approach; i.e. 
genes thought to be involved in radiotherapy toxicity are studied. 
Such genetic associations have proved difficult to replicate. More 
recently studies have used a genome-wide approach, where the whole 
genome is screened for genetic variations associated with 
radiotherapy toxicity. GWAS studies of radiotherapy toxicity have 
shown evidence that genetic variations that are associated with late 
radiotherapy toxicity exist. Power calculations from such GWAS 
suggest that future studies should include more than 2500 
participants. Meta-analysis of GWAS studies in the radiogenomics 
consortium is currently underway to achieve such numbers. Continuing 
recruitment of patients into studies within the Radiogenomics 
Consortium is essential so that sufficiently powered studies can be 
performed, and methodological challenges addressed. 
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Purpose/Objective: Parametrial boost (PB) is used in advanced cancer 
cervix to increase the dose in regions where contribution from 
intracavitary brachytherapy (IC BT) is insufficient. Midline block is 
then used to protect midline organs at risk (OAR). However as stated 
by IAEA (2010), the efficacy of parametrial boosts has not been 
systematically tested and there is little literature evidence to support 
its routine use. 
An alternative technique for parametrial boosting is the combined 
intracavitary and interstitial (IC/IS) BT. The purpose of our study is to 
evaluate the dose delivered by IC BT and PB and compare it to IC/IS 
BT.  
Materials and Methods: We evaluated 51 consecutive patients with 
parametrial involvement at diagnosis. At BT 23 patients had persistent 
parametrial involvement necessitating combined IC/IS BT. For the 23 
patients we compared optimised IC BT combined with external beam 
PB field to the delivered optimised IC/IS BT. Whole pelvis conformal 
EBRT 45-50 Gy /25-30 fx and PDR BT 15-17.5 Gy x 2fx IC/IS was 
delivered. PB field was created as an external beam AP/PA field of 9 
Gy / 5fx, with midline block conformed to the isodose line 85 Gy and 
of at least 4 cm width. For the PB scenario summation of doses from 
EBRT plus an optimised IC BT plan and PB fields were used. The 
physical 3D dose distribution was converted to the EQD2 using α/β = 
10 Gy for tumour, and = 3 Gy for OAR with T½ = 1.5 hr. DVH 
parameters obtained in total EQD2 were GTV, HR CTV, IR CTV: D90, 
D100 and D2cm3for rectum, bladder, sigmoid and bowel. 
Testing the impact of organ movement was done by shaking the EQD2 
dose map 1 cm bilaterally and reading out the DVH parameters. 
The normal tissue volume irradiated to 60 Gy EQD2 (total EBRT+BT) 
was measured.  
Results: Table 1 shows mean total EQD2+SD (Gy) of IC+PB versus IC/IS 
BT. With IC+PB, 3 patients had < 79 Gy to the HR CTV D90 while IC/IS 
resulted in doses >84Gy for all patients. Comparing the target dose 
delivered by the shifted dose map to PB resulted in a difference of 1.0 
± 1.8 Gy for HR CTV D90, and - 1.0 ± 1.8 Gy for IR CTV D90. OAR D2cm3 
changed by 0.8 ± 1.3 Gy, 0.7 ± 1.0, 0.4 ± 2.6 Gy and 0.1 ± 2.8 Gy for 
bladder, rectum, sigmoid and bowel respectively. 
The PB resulted in a significantly higher V60 as compared to the IC/IS: 
For the IC/IS technique the mean V60 was 228.4 ± 81.5 cm3 and for 
the IC + PB it was 593.5 ±595.6 cm3 (p= 0.004). 
 
  
Conclusions: Midline blocked fields significantly increases dose by 5-9 
Gy to the D2cm3 of the rectum, sigmoid, bladder and bowel as 
compared to IC/IS, but was robust in terms DVH parameters for the 
'shaked' EQD2 dose map. Mean HR CTV D90 were comparable for both 
techniques, however PB resulted in significant underdosage for 3 
cases. With EBRT PB, large volume is irradiated to at least 60 Gy 
which may result in increased clinical morbidity expressed by this 
irradiated bowel and normal tissue. IC/IS compared to IC + PB spares 
better the OAR and deliver a more conformed RT to the targeted area 
with less normal tissue volume receiving 60Gy. 
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Purpose/Objective: In radiotherapy for cervix cancer elective and 
pathological lymph nodes (LN) in the pelvis, abdomen and inguinal 
regions are irradiated to a certain dose during external beam 
radiotherapy (EBRT).  
However the LNs will also receive a fraction of dose during 
brachytherapy (BT).  
This study aims to 1) evaluate the BT dose contribution to LN groups, 
2) compare LN doses from standard non-optimised PDRBT and 
optimised MRI guided PDR BT. 
Materials and Methods: 25 consecutive patients who received whole 
pelvis 3D conformal EBRT (45-50Gy in 25 or 30 fractions) and 2 
fractions of MRI guided PDR BT (each 15 or 17.5Gy) were analysed. LN 
groups were delineated as follows: para-aortic (PAN), common (CI), 
external (EI) and internal (II) iliac, obturator (OB), inguinal (ING), and 
presacral (PS). For each group D98%, D50% and D2% for full optimised 
BT were compared to those forstandard non-optimised BT. BT dose 
was normalised to a 2Gy fraction size (EQD2) using the linear 
quadratic model (α/β=10Gy, T1/2=1.5h). Correlation between TRAK 
and dose was assessed for all LNs with linear regression. 
Results: As shown in table 1 BT contributed with considerable dose 
(mean D50% was 3.8-6.2Gy) to the pelvic LNs (EI, II, OB, PS) in 
optimised plans. Less dose contribution was seen in CI, PAN (mean 
D50% was 0.5-1.9 Gy) and ING (1.5 Gy). Large inter-patient variation 
was seen with SDs of up to 2.6 Gyof D50%. For non-optimised BT D50% 
doses to PAN, CI and ING ranged from 0.6 to 2.7 Gy and to pelvic LN it 
ranged from 4.1 to 6.4 Gy.As shown in Table 1, a generally smaller 
dose to different LN-stations was delivered by the optimised plan 
compared to the standard plan. This is compatible to the efforts of 
creating a more conformal BT with dose optimisation. However, 
although differences were statistically significant for most LNs, they 
only amounted toa mean of 0.2 - 0.9 Gy (D50%). This difference can 
be explained by the overall reduction of the TRAK in the optimised 
plan by 0.25cGy±0.3 (p=0.0005) compared to the standard BT plan. 
This also explains the higher dose reduction (appr25%) to the 
abdominal LN group, compared to the LN dose reduction in the pelvic 
area close to HR - CTV (appr 10%). The dwell positions in the tip of the 
tandem are not used to the same degree in the optimised plan as in 
the standard plan,where all the positions are equally loaded. 
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TRAK correlated with LN dose, however, with linear regression R2 was 
less than 0.3 for all LNs which indicates that TRAK cannot be used to 
predict LN dose. 
 
 
Conclusions: BT contributes with considerable dose to pelvic LNs, and 
should be considered in the evaluation of total LN dose,in particular 
when pathological LNs are boosted. In our study the optimised 
BTcontributed with a range of 3.8 - 6.2Gy (D50%) to pelvic LN and 0.5-
1.9 to PAN,CI and ING (D50%). Image guided BT plan optimization had 
minor impact on BT contribution to LN dose.  
   
OC-0358   
MRI guided adaptive cervical cancer brachytherapy: Impact of 
repeated intrafractional imaging.  
C.N. Nomden1, A.A.C. de Leeuw1, H. Westerveld2, M.A. Moerland1, 
J.M. Roesink1, J.H.A. Tersteeg1, I.M. Jürgenliemk-Schulz1 
1University Medical Center Utrecht, Radiotherapy, Utrecht, The 
Netherlands  
2Amsterdam Medical Center, Radiotherapy, Amsterdam, The 
Netherlands  
 
Purpose/Objective: To assess the impact of organ movement and 
deformation on tumour and organ at risk (OAR) dose parameters by 
repeating MR imaging during individual brachytherapy (BT) fractions. 
Materials and Methods: Multiple MR scans during BT were performed 
in 12 patients treated with external beam radiotherapy (EBRT), 
chemotherapy and high dose rate (HDR) image guided adaptive BT. 
The BT schedule consisted of two HDR applications delivering two 
fractions each (2 times 2 fractions of 7Gy). A set of T2-weighted 
transversal, sagittal and coronal MR scans was acquired after insertion 
of the applicator (MRplan). High risk clinical target volume (HR-CTV) 
and the organs at risk (bladder, rectum, and sigmoid) were delineated 
and treatment planning was conducted directly on MR images. Prior to 
irradiation a second MRI set (MRprerad) was obtained. An onset 
applicator based registration with MRplan made evaluation of OAR 
position and volume changes before irradiation possible. Adaptations, 
e.g. deflating gas from the rectum, were applied to several patients 
to keep the rectum at MRprerad similar to the planned situation 
(MRplan). Applicator insertions, MR imaging and HDR dose delivery 
were performed in an adapted BT operation theatre, with afterloader 
secured to the wall. 
For research purposes the treatment plan was evaluated on the 
contours of MRprerad. Calculated dose differences between MRplan 
and MRprerad indicate changes between planned and received dose. 
These differences were evaluated and compared to the data obtained 
in a group of 10 patients that received repeated MR imaging during 
pulsed dose rate (PDR) BT.  
Results: The planned mean total dose (EBRT + BT) for the D90 HR-CTV 
and D2cc of bladder, rectum, and sigmoid were 86±6, 84±9, 64±9, and 
62±6 Gy EQD2, respectively. The mean differences between the 
planned dose and the received dose calculated on MRprerad were 
0.6±1.9, -0.7±3.6, 0.7±4.7, and 1.2±2.9 Gy EQD2, respectively. 
Analyses per HDR fraction (n=48) showed variety in physical mean 
dose differences; -1.0±3.7, -1.5±7.5, 2.6±18.6, and 4.7±21.8 %, 
respectively. The mean differences were small, but large ranges 
occurred especially for rectum and sigmoid of (-59-42) and (-34-76) %, 
respectively (figure1). However, despite these differences OAR 
constraints were exceeded in only 3 patients. Comparison with the 
PDR data showed a reduction of mean and standard-deviation of the 
calculated dose differences of the OAR. In particular for rectum and 
sigmoid, during PDR the mean differences increased systematically 20-
30% compared to only 3-5% in HDR treated patients.  
Conclusions: The introduction of MRprerad results in a more accurate 
estimate of the dose delivered to the patient. Visualization of 
anatomical changes prior to irradiation allows individualized 
interventions and adaptations which can reduce dose uncertainties in 
rectum and sigmoid.  
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Purpose/Objective: Little data exists on the effect of variations of 
bladder volume (BV) on toxicity outcomes for image-guided 
intracavitary brachytherapy (ICB) for cervical cancer. Limited data has 
shown that variable bladder filling at each fraction can vary the 
position of hot spots within the bladder. Recently, it has become our 
center's policy to alternate between small (60cc) and large (300cc) 
bladder filling with the assumption that this might reduce long-term 
bladder toxicity. Objective of this study was to determine if there was 
a correlation between BV variation and long-term bladder toxicity.  
Materials and Methods 
Data for patients treated with ICB from 2008 to 2012 in 3 centers was 
prospectively collected. Patients received 45 Gy in 25 fractions of 
pelvic ± para-aortic EBRT with concurrent chemotherapy followed by 4 
to 5 fractions of ICB. Patient-reported toxicity was measured with 
LENT-SOMA questionnaires at the time of follow-up visits. Dose 
parameters including HR-CTV D90 Bladder D2cc, ICRU bladder dose 
points and BV (based on CT contour) were recorded for each ICB 
fraction. A total dose in EQD2 was generated for each dose 
parameter. Standard deviation for bladder BV between the 4-5 
fractions in each patient was used as a surrogate measure of bladder 
volume variability. Univariate linear regression analyses were 
completed to determine if there was significant correlation between 
dose parameters or BV variabilty and LENT-SOMA bladder scores. 
Results: 79 patients were treated between 2008 and 2012 with ICB for 
cervical cancer with CT-based planning. 45 had stage I, 24 stage II, 9 
stage III and 1 stage IV. ICB dose was 30 Gy in 5 fractions of 6 Gy for 
85% of patients, 26Gy in 4 fractions of 6.5Gy for 7,5% and various 5 
fraction schedules of 26 to 32 Gy for 7.5%. Median follow-up was 22.4 
months. 42 patients had a LENT-SOMA bladder score of 0, 31 had 
grade 1 toxicity, 5 had grade 2 toxicity and 1 had grade 3 toxicity. 
Median total HR-CTV D90 EQD2 was 46.6 Gy10 for ICB alone and 90.6 
Gy10including contribution of EBRT. Median total bladder 2cc EQD2 for 
ICB was 36,9 Gy3. Median interfraction standard deviation (SD) of BV 
was 45.3cc (range: 3.7-178.6). All tests for HR-CTV D90, Bladder D2cc 
and ICRU bladder dose point were not statistically significant for 
correlation with LENT-SOMA bladder scores. Regression analysis for 
bladder volume SD vs.LENT-SOMA scores was statistically significant 
